Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 4/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CDC25A | P30304 | 2/20 | 0.43 |
| ▸ | CDC25C | P30307 | 2/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | CCR6 | P51684 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | CLEC4M | Q9H2X3 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL272962 | 0.86 | PDE4B (0.51) | CDC25BKDRTSHRKDM4EALDH1A1 | |
| SCHEMBL7667798 | 0.81 | HSD11B1 (0.40) | TSHRKDM4EALDH1A1MAOBHSD11B1 | |
| SCHEMBL11272281 | 0.81 | CDC25B (0.60) | CDC25BTSHRKDM4EALDH1A1CDC25A | |
| SCHEMBL8613925 | 0.81 | TSHR (0.47) | TSHRKDM4EALDH1A1HSD11B1KMT2A | |
| SCHEMBL12788120 | 0.80 | STS (0.47) | TSHRKDM4EALDH1A1HSD11B1KMT2A | |
| SCHEMBL11955735 | 0.79 | KDM4E (0.47) | CDC25BTSHRKDM4EALDH1A1MAOA | |
| SCHEMBL4472069 | 0.79 | TSHR (0.46) | CDC25BTSHRKDM4EALDH1A1CDC25A | |
| SCHEMBL5738305 | 0.79 | HSD11B1 (0.43) | TSHRALDH1A1HSD11B1ADORA1 | |
| SCHEMBL5865527 | 0.79 | STS (0.52) | KDM4EALDH1A1MAOBHSD11B1PPARG | |
| SCHEMBL13057679 | 0.79 | STS (0.44) | KDM4EALDH1A1MAOBHSD11B1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158665-B2 | Farnesoid X receptor agonists | GLAXOSMITHKLINE LLC (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158665-B2 | Farnesoid X receptor agonists | GLAXOSMITHKLINE LLC (US) | 2012-04-17 | — | — | US | disclosed |
| EP-1962838-B1 | FARNESOID X RECEPTOR AGONISTS | GLAXOSMITHKLINE LLC (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20100160398-A1 | Farnesoid X Receptor Agonists | GLAXOSMITHKLINE LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100160398-A1 | Farnesoid X Receptor Agonists | GLAXOSMITHKLINE LLC | 2010-06-24 | — | — | US | disclosed |
| US-7705028-B2 | Farnesoid X receptor agonists | GLAXOSMITHKLINE LLC (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705028-B2 | Farnesoid X receptor agonists | GLAXOSMITHKLINE LLC (US) | 2010-04-27 | — | — | US | disclosed |
| EP-1962838-A2 | FARNESOID X RECEPTOR AGONISTS | Smithkline Beecham Corporation (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20080167356-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167356-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2007076260-A2 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007076260-A2 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167356-A1 | FARNESOID X RECEPTOR AGONISTS | NR1H4, NR1H3, NR1H2 | CDC25B 4428/4885KDR 2696/4885TSHR 486/4885 |
| US-20100160398-A1 | Farnesoid X Receptor Agonists | NR1H4, NR1H3, NR1H2 | CDC25B 4428/4885KDR 2696/4885TSHR 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.